Sandu Pharmaceuticals Announces 41st AGM Details and Dividend

Final Dividend: Rs 1 per share for FY 2025-26
Record Date for Dividend: September 4, 2026

Reader Takeaway: Dividend payout and RPT approval are key for shareholders; governance changes signal transition.

What just happened

Sandu Pharmaceuticals Ltd has announced the date for its 41st Annual General Meeting (AGM) on September 11, 2026. The company's board has recommended a final dividend of Rs 1 per share for the financial year 2025-26. Shareholders will also vote on material related party transactions and significant corporate governance changes, including auditor appointments and leadership restructuring.

Why this matters

The AGM agenda includes several points critical for shareholders. The proposed final dividend offers a direct return on investment. Approving related party transactions up to Rs 100 crore with Sandu Brothers Private Limited requires careful consideration due to its scale. Additionally, changes in auditors and management roles will shape the company's future direction and governance.

The backstory

Sandu Pharmaceuticals has a history of operations in the pharmaceutical sector. This AGM continues its annual corporate governance cycle, with proposed changes aimed at long-term stability and compliance. The proposed related party transaction limit is a significant figure, indicating continued business relationships with Sandu Brothers.

What changes now

If approved at the AGM, shareholders will receive a Rs 1 per share dividend. The company will also have a new statutory auditor, M/s. Dave & Dave, for five years. Shri Balram Viswanathan is proposed to become Chairman and Managing Director, and Smt. Dr. Neeti Madan Kapre will join as an Independent Director, pending approvals.

Risks to watch

Shareholders should scrutinize the related party transaction proposal, ensuring it is indeed on an arm's length basis. Changes in key management and audit firms can also introduce a temporary period of adjustment or uncertainty.

Peer comparison

While specific peer dividend policies and RPT thresholds vary, Sandu Pharma's proposed dividend is a typical payout mechanism. The scale of the RPT requires comparison with similar transactions in the industry to gauge its appropriateness.

Context metrics

• Final Dividend for FY 2025-26: Rs 1 per share.
• Record Date for Dividend: September 4, 2026.
• Proposed Related Party Transaction limit: Up to Rs 100 crore (aggregate) until FY 2027.
• Cost Auditor Remuneration for FY 2026-27: Rs 1.30 lakh.
• Proposed Managing Director Salary for FY 2026-27: Rs 45 lakh.

What to track next

Investors should monitor the outcomes of the AGM, especially the voting results for the dividend, related party transactions, and board appointments. Reviewing the full annual report will provide deeper insights into the financial performance and strategic rationale behind these proposals.